Brief: Linc Portfolio Co Announces Positive Phase II Study Results

Linc AB

04/11/2022 07:13

Nov 4 (Reuters) - Linc AB  LIC.ST :
    * PORTFOLIO CO CINCLUS PHARMA ANNOUNCES POSITIVE TOPLINE
RESULTS
PHASE II STUDY REGARDING DRUG CANDIDATE LINAPRAZAN GLURATE

Source text for Eikon:  ID:nMFNb7lGqq 
Further company coverage:  LIC.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))